Literature DB >> 18459553

SodiumPhosphate (NaP) versus polyethylene glycol-electrolyte lavage solution (PEG-ELS) tolerability: a prospective randomized study in patients with gynecological malignancy.

F B Cebesoy1, O Balat, S Pence.   

Abstract

PURPOSE: The aim of the study was to evaluate patient tolerability and compliance to two bowel cleansing agents (PEG-ELS and NaP) as well as to compare the cost effectiveness.
METHODS: Three hundred and forty-three consecutive patients were randomized to receive either the standard 4 1 of polyethylene glycol and electrolyte lavage solution (PEG-ELS) or 90 ml of sodium phosphate (NaP). All patients were advised to be on a clear liquid diet one day before starting the bowel cleansing regimen and to take ornidazole orally (3 x 2 tablets) 24 hours before surgery. Patient tolerabilty and compliance to the regimens were assessed based on complaints of nausea, vomiting and the need of antiemetics. In addition completion of the regimens was evaluated in both groups.
RESULTS: The need for antiemetics because of nausea and vomiting was statistically higher in the PEG-ELS group than the NaP group (p = 0.000). Regimen completion rate was statistically higher in the NaP group than in the PEG-ELS group (p = 0.000). NaP is more cost effective than PEG-ELS.
CONCLUSION: NaP was rated superior to PEG-ELS in terms of patient tolerability, compliance, completion of the regimen and cost effectiveness and should be the first-choice treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18459553

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  1 in total

1.  A Randomized Prospective Study of Bowel Preparation for Colonoscopy with Low-Dose Sodium Phosphate Tablets versus Polyethylene Glycol Electrolyte Solution.

Authors:  Erina Kumagai; Tomoyoshi Shibuya; Masae Makino; Takashi Murakami; Shiori Takashima; Hideaki Ritsuno; Hiroya Ueyama; Tomohiro Kodani; Hitoshi Sasaki; Kenshi Matsumoto; Naoto Sakamoto; Taro Osada; Akihito Nagahara; Tatsuo Ogihara; Sumio Watanabe
Journal:  Gastroenterol Res Pract       Date:  2014-09-15       Impact factor: 2.260

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.